NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









American Gene Technologies

American Gene Technologies

Private
Rockville, MarylandHealthcare & Life Scienceshttps://www.americangene.com/

Last Round

Convertible Debt

Oct 31, 2023

Est. Valuation

$15.21M

Total Funding Raised

$73.73M

Company Overview

American Gene Technologies is a biotechnology company that develops gene and cell therapies aimed at curing infectious diseases, cancers, and inherited disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapycell therapyHIV functional curelentiviral vectorgenetic medicinebiotechclinical-stage biotechHIV cure researchgene delivery technologyoncology therapyclinical trialsdrug developmenttranslational medicinebiotech startuppharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

American Gene Technologies Comps

Public and private peers based on sector, stage, and business model.

American Gene Technologies comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

American Gene Technologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Convertible DebtOct 31, 2023
Series FSep 22, 2023
M&AAug 9, 2023
Series FApr 22, 2022
VC RoundApr 15, 2021
Series C
Nov 1, 2015

Key People

Founding team and executive leadership

Jeff Galvin

Chief Executive Officer, Investors We Are Pioneering Disease Solutions to Achieve Permanent Cures for Human Diseases, Advanced Gene & Cell Therapy Platform Yielding Cures for Serious Diseases CEO

Executive Team

American Gene Technologies Investors

Notable investors and investment history

American Gene Technologies investors
InvestorRounds
HealthTech Fund (An Alumni Ventures Fund)Series D
ROC Venture GroupSeries F
Ride Wave VenturesSeries F
NIH RADxGrant
GaingelsVC Round
10X Capital Venture Acquisition Corp. IIIM&A
Alumni VenturesSeries F, Series D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 22, 2025

    Presented at the International AIDS Society 2025 conference.

  • Jul 22, 2025

    Promising results from AGT103-T HIV functional cure program presented at IAS 2025.

American Gene Technologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

American Gene Technologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about American Gene Technologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersRockville, Maryland
Employee Range26
Year Founded2007
Last FundingOct 31, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.